The Impact of Minimal Residual Disease in Acute Lymphoblastic Leukemia

June 16, 2017

[Click here to enlarge.] 

Presentation

Click Here


 

Topics Covered

We invite you to learn more about:

  • ​Current treatment options for patients living with ALL
  • The impact of minimal residual disease (MRD)
  • Clinical trials and emerging therapies for ALL treatment
  • The importance of open communication with your healthcare team to promote a better quality of life


 

Speaker

Daniel J. DeAngelo, M.D., Ph.D.
Adult Leukemia Program
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
 

Program Support

Support for this program provided by 


 

For any questions or comments about this program, please email [email protected].

< Back to Webcasts